Schizophrenia

Plant-based concept
#Botanical #Jaguar Health #License agreement #Neuroscience #Plant-based #Schizophrenia

Jaguar Health out-licenses plant-based drug for schizophrenia

Jaguar Health’s out-licensing agreement with Magdalena Biosciences to develop novel, natural prescription medicines derived from plants for mental health indications, has been expanded. The agreement now includes the ethnobotanical know-how related to development of a prescription drug compound from a specified medicinal plant for possible schizophrenia and psychoses indications and… Read More

#Business & Investment #News

#Blood brain barrier #Calliditas Therapeutics #Cancer #Cancer research #Clinical trials #Drug discovery #Head and neck cancer #Immunotherapy #Neuroscience #Oncology #Plant-based #Schizophrenia #Smoking cessation #Squamous cell carcinoma #Vaping

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  A leading news story this week has been the announcement of positive Phase II… Read More

#News

#Blood brain barrier #Calliditas Therapeutics #Cancer #Cancer research #Clinical trials #Drug discovery #Head and neck cancer #Immunotherapy #Neuroscience #Oncology #Plant-based #Schizophrenia #Smoking cessation #Squamous cell carcinoma #Vaping

This week in drug discovery (6-10 May) 

News round-up for 6-10 May by DDW Multimedia Editor Megan Thomas. A leading news story this week has been the announcement of positive Phase II results of a head and neck cancer trial, but there have been a number of other interesting clinical result announcements. These include the… Read More

#News

Human brain
#Clinical trial #Neuroscience #Newron Pharmaceuticals #Schizophrenia

Study in schizophrenia patients shows positive top-line results 

Newron Pharmaceuticals has announced positive top-line results from its potentially pivotal study 008A, evaluating the safety, tolerability and efficacy of evenamide (30 mg bid) in patients with chronic schizophrenia currently being treated with a second-generation antipsychotic including clozapine, but demonstrating an inadequate response to that treatment.   The… Read More

#News

#ALS #Autism #Neurology #Neuroscience #Schizophrenia

This week in drug discovery (1-5 April) 

News round-up for 1-5 April by DDW Digital Content Editor Diana Spencer. This has been a busy week in the field of neuroscience drug discovery, with EU approval for a long-acting schizophrenia treatment, research revealing new insights into autism, the formation of a partnership focused on ALS drug… Read More

#News

#European Commission #Neuroscience #Otsuka #Schizophrenia

EU approves long-acting injectable for schizophrenia

Abilify Maintena 960mg (aripiprazole) has been approved in the EU as the first once-every- two-months long-acting injectable for the maintenance treatment of schizophrenia. The new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months. Aripiprazole once-every-two-months LAI is a new formulation containing 960mg aripiprazole provided in a… Read More

#News #Regulatory

#Financing #Neurology #Neurosterix #Schizophrenia #Start-ups

$63m for allosteric modulators for neurological disorders

Neurosterix has launched with a $63 million Series A financing led by Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures. The company will acquire Addex’s allosteric modulator discovery technology platform. The platform has a track record of identifying highly… Read More

#Editor's Choice #News #Start-up Zone

#Allergy #CHMP #FDA #Melanoma #Regulatory #Schizophrenia #Scleroderma

This week in drug discovery (26 Feb – 1 March) 

News round-up for 26 Feb – 1 March by DDW Digital Content Editor Diana Spencer. The news highlights this week all focus on regulatory decisions, both positive and negative. The first therapy was approved for allergic reactions to food, a drug for scleroderma secured Fast Track Designation, and… Read More

#News

#FDA #Finance #GlobalData #Minerva Biosciences #Neuroscience #Schizophrenia

Minerva value plummets following FDA rejection of roluperidone

The stock market value of Minerva Biosciences has dropped nearly 60%, following the US Food and Drug administration (FDA) decision not to approve roluperidone for symptoms of schizophrenia. The company received a ‘Complete Response Letter’ from the FDA highlighting the clinical deficiencies in its new drug… Read More

#News #Trending News

Human brain
#Clinical trial #Neuroscience #Newron Pharmaceuticals #Schizophrenia #Treatment resistance

“Highly encouraging” results for schizophrenia drug

Milan-based Newron Pharmaceuticals has reported “exceptional” one-year results from study 014/15 into evenamide as an add-on to antipsychotics for the management of treatment-resistant schizophrenia (TRS). The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of… Read More

#News

#Cancer research #Dementia #Motor neurone disease #Neuroscience #Osteoarthritis #Schizophrenia

New DDW Highlights episode out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The news highlights this week are mostly focused around neuroscience, with new guiding principles… Read More

#News

#Cancer research #Dementia #Motor neurone disease #Neuroscience #Osteoarthritis #Schizophrenia

This week in drug discovery (4-8 December) 

News round-up for 4-8 December by DDW Digital Content Editor Diana Spencer. The news highlights this week are mostly focused around neuroscience, with new guiding principles and a drug repurposing fund launched for motor neuron disease research, a new drug target found for early-onset dementia, and a… Read More

#News

#Neumora Therapeutics #Neuropsychiatric disorders #Neuroscience #Phase I trial #Schizophrenia #Vanderbilt University

Potentially game-changing schizophrenia drug enters trials

A potential schizophrenia treatment, discovered at Vanderbilt University in Tennessee in the US, has been cleared by the US Food and Drug Administration for use in Phase I clinical trials. NMRA-266, an allosteric modulator that works through a mechanism that has been clinically validated in the treatment of disorders like… Read More

#Editor's Choice #News #Regulatory

Female medical researcher
#Genetics #Genetics / genomics #Icahn School of Medicine #Neuroscience #Psychiatry #Schizophrenia

Researchers identify genes that may increase schizophrenia risk

Researchers have identified two previously unknown genes linked to schizophrenia and newly implicated a third gene as carrying risk for both schizophrenia and autism. Led by the Icahn School of Medicine at Mount Sinai, the multi-centre study further demonstrated that the schizophrenia risk conferred by these… Read More

#News

Degeneration of dopaminergic neuron
#Clinical trial #Neurology #Neuroscience #Newron Pharmaceuticals #Phase II trial #Schizophrenia

Evenamide could ‘open new treatment pathways’ for TRS

Newron Pharmaceuticals’ Evenamide could be a potential breakthrough treatment in the management of treatment-resistant schizophrenia (TRS) patients, according to new trial data.  The drug is being assessed as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe TRS who are not responding to… Read More

#Editor's Choice #News

#ALS #Cerevance #Financing #Funding #Neurology #Parkinson's #Schizophrenia

$116 million financing will support neurological disease trials

Cerevance has expanded its Series B funding round with an additional close of $51 million, bringing the total to $116 million.  The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.   “We are thrilled to secure additional funding from world-class investors who strongly… Read More

#Business & Investment #News